| 000 | 01567 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250518100618.0 | ||
| 264 | 0 | _c20210806 | |
| 008 | 202108s 0 0 eng d | ||
| 022 | _a1933-2874 | ||
| 024 | 7 |
_a10.1016/j.jacl.2020.03.001 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDaniels, Stephen | |
| 245 | 0 | 0 |
_aPCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study. _h[electronic resource] |
| 260 |
_bJournal of clinical lipidology _c |
||
| 300 |
_a322-330.e5 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xtherapeutic use |
| 650 | 0 | 4 |
_aAnticholesteremic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHeterozygote |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHyperlipoproteinemia Type II _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPCSK9 Inhibitors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aCaprio, Sonia | |
| 700 | 1 | _aChaudhari, Umesh | |
| 700 | 1 | _aManvelian, Garen | |
| 700 | 1 | _aBaccara-Dinet, Marie T | |
| 700 | 1 | _aBrunet, Aurelie | |
| 700 | 1 | _aScemama, Michel | |
| 700 | 1 | _aLoizeau, Virginie | |
| 700 | 1 | _aBruckert, Eric | |
| 773 | 0 |
_tJournal of clinical lipidology _gvol. 14 _gno. 3 _gp. 322-330.e5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.jacl.2020.03.001 _zAvailable from publisher's website |
| 999 |
_c30898126 _d30898126 |
||